Research and Markets (http://www.researchandmarkets.com/research/dt9k5f/opportunities_in) has announced the addition of the "Opportunities in the Global Human Embryonic Stem Cell (hESC) Products Market 2013-2017" report to their offering.

It is also crucial for companies involved in the hESC product marketplace to understand the funding environment which supports hESC research. Within the United States, the federal government is currently an important, although not dominant, source of funding for stem cell research. The reason is that U.S. states are spending almost as much as the federal government on stem cell research and are actually spending more than the federal government on human embryonic stem cell (hESC) research. Private sources also contribute a huge amount of funding to stem cell research, with analysis of recent large gifts summing to over $1.7 billion.

Worldwide, hESC funding also varies widely, with countries varying from very permissive to very limited in how each elects to fund hESC product and technology development within the federal, private, and not-for-profit sectors.

While there is conclusive evidence that entering the hESC marketplace is financially worthwhile, there are complicating factors for companies that hope to enter the market. Specifically, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.

As such, this market research report explores the complex intellectual property (IP) landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives - such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species.

Key Findings Include:

- Charts, Trends, and Metrics for the hESC Product Market

- Trends for hESC Grants, Scientific Publications, and Patents

- 5-Year Market Size Projections (2013-2017)

- Profitable Opportunities for hESC Product and Technology Development

- Consumer Behavioral Patterns and Preferred Providers

- Preferred Species for ESC Research

- Crucial Trends and Unmet Market Needs

- Breakdown of the Marketing Methods Used by Industry Participants

- Tested Sentences for Selling to hESC Scientists

- End-User Survey of hESC Researchers (101 U.S. / 146 International)

Key Topics Covered:

I. STRATEGIC OVERVIEW

II. ACCESS & AVAILABILITY OF hESC LINESs

III. END-USER APPLICATIONS OF hESCs

IV. PATENT ENVIRONMENT

V. MARKET TREND ANALYSIS - FUTURE GROWTH PROJECTIONS

VI. MARKET SIZE

VII. MARKET CHARACTERIZATION

VIII. hESC RESEARCH SUPPLY COMPETITORS

IX. SPECIALTY PHARMACEUTICAL COMPANIES DEVELOPING hESC THERAPIES

X. TOXICOLOGY TESTING LEGISLATION

XI. STRATEGIC PRODUCT & TECHNOLOGY DEVELOPMENT

XII. STRATEGIES FOR ACCESSING THE MARKETPLACE

XIII. SCIENTIST PANEL: DETAILED END-USER SURVEY

XIV. CONCLUSIONS

Companies Mentioned

- Australian Stem Cell Centre

- BD Biosciences

- Cellartis AB

- Chemicon

- Geron

- Invitrogen

- Novocell

- R&D Systems

- SA Biosciences

- Tataa Biocenter

- Thermo Scientific

- Vitrolife

For more information visit http://www.researchandmarkets.com/research/dt9k5f/opportunities_in

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Biotechnology